Find Cetuximab manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0INTERMEDIATES

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

3 RELATED EXCIPIENT COMPANIES

3EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as:
Molecular Formula
C57H64FN13O15
Molecular Weight
1190.2  g/mol
InChI Key
JYEFSHLLTQIXIO-SMNQTINBSA-N

Cetuximab
1 2D Structure

Cetuximab

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;5-fluoro-1H-pyrimidine-2,4-dione
2.1.2 InChI
InChI=1S/C33H38N4O6.C20H23N7O7.C4H3FN2O2/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2;21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30;5-2-1-6-4(9)7-3(2)8/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3;1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32);1H,(H2,6,7,8,9)/t33-;12?,13-;/m00./s1
2.1.3 InChI Key
JYEFSHLLTQIXIO-SMNQTINBSA-N
2.1.4 Canonical SMILES
CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.C1C(N(C2=C(N1)NC(=NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O.C1=C(C(=O)NC(=O)N1)F
2.1.5 Isomeric SMILES
CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.C1C(N(C2=C(N1)NC(=NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O.C1=C(C(=O)NC(=O)N1)F
2.2 Create Date
2012-03-21
3 Chemical and Physical Properties
Molecular Weight 1190.2 g/mol
Molecular Formula C57H64FN13O15
Hydrogen Bond Donor Count10
Hydrogen Bond Acceptor Count20
Rotatable Bond Count14
Exact Mass1189.46288655 g/mol
Monoisotopic Mass1189.46288655 g/mol
Topological Polar Surface Area386 A^2
Heavy Atom Count86
Formal Charge0
Complexity2310
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count3

JDMF

read-more
read-more

01

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Cetuximab bulk concentrate

Registration Number : 301MF10063

Registrant's Address : Zone industriale de l'Auriettaz, Rue de l'Auriette 151, 1170 Aubonne, Switzerland

Initial Date of Registration : 2019-09-11

Latest Date of Registration : 2020-08-05

blank

02

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Cetuximab bulk concentrate

Registration Number : 305MF10129

Registrant's Address : Zone industriale de l'Auriettaz, Rue de l'Auriette 151, 1170 Aubonne, Switzerland

Initial Date of Registration : 2023-12-06

Latest Date of Registration : 2023-12-06

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

arrow
Biotech Showcase
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMesochem is focused on incessant innovation along with the R&D of new APIs.

Flag China
Digital Content Digital Content

Cetuximab

About the Company : Beijing Mesochem Technology Co. Ltd., which is located in the national economic and technological development area of Yizhuang, China, manufactures pharmaceutical chemicals, fine c...

Beijing Mesochem Technology Co. Ltd., which is located in the national economic and technological development area of Yizhuang, China, manufactures pharmaceutical chemicals, fine chemicals and fundamental chemical materials. It has an efficient research and development team. Beijing Mesochem provides its customers customized development, craft optimization, contract customization and outsourcing services. The company has a well-established industrial base in Weinan, Shanxi Province. The production base features a 20,000 ㎡ plant with a production capacity of over 8,000 MT per year.
Mesochem Company Banner

02

arrow
Biotech Showcase
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

Flag China
Digital Content Digital Content

Cetuximab

About the Company : ​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...

​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in Nantong, Jiangsu and Jinan, Shandong, with more than 13,000㎡ of production sites. While supplying products to customers, the company also provides services such as technology development, technology transfer and technology exchange, aiming to provide customers with comprehensive supply and solutions in the biomedical industry.
Shanghai Minbiotech CB
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

TTX-080 is a novel, first-in-class antibody targeting HLA-G. Patients with biomarker-defined metastatic colorectal cancer (mCRC) in combination with cetuximab and FOLFIRI.


Lead Product(s): TTX-080,Cetuximab

Therapeutic Area: Oncology Brand Name: TTX-080

Study Phase: Phase IProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 31, 2024

blank

01

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Lead Product(s) : TTX-080,Cetuximab

Therapeutic Area : Oncology

Highest Development Status : Phase I

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : TTX-080 is a novel, first-in-class antibody targeting HLA-G. Patients with biomarker-defined metastatic colorectal cancer (mCRC) in combination with cetuximab and FOLFIRI.

Brand Name : TTX-080

Molecule Type : Large molecule

Upfront Cash : Not Applicable

October 31, 2024

blank

Details:

The collaboration aims to evaluate BND-35 in combination with Merck's anti-EGFR monoclonal antibody Erbitux (cetuximab) in a Phase 1 for unresectable or metastatic solid tumors.


Lead Product(s): BND-35,Cetuximab

Therapeutic Area: Oncology Brand Name: BND-35

Study Phase: Phase IProduct Type: Large molecule

Sponsor: Merck Group

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration October 29, 2024

blank

02

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : The collaboration aims to evaluate BND-35 in combination with Merck's anti-EGFR monoclonal antibody Erbitux (cetuximab) in a Phase 1 for unresectable or metastatic solid tumors.

Brand Name : BND-35

Molecule Type : Large molecule

Upfront Cash : Undisclosed

October 29, 2024

blank

Details:

QTX3046, a novel orally bioavailable, brain-penetrant, non-covalent allosteric KRASG12D inhibitor has announced dosing of first patient in Phase 1/1b trail for the treatment of advanced solid tumors.


Lead Product(s): QTX3046,Cetuximab

Therapeutic Area: Oncology Brand Name: QTX3046

Study Phase: Phase IProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 27, 2024

blank

03

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Lead Product(s) : QTX3046,Cetuximab

Therapeutic Area : Oncology

Highest Development Status : Phase I

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : QTX3046, a novel orally bioavailable, brain-penetrant, non-covalent allosteric KRASG12D inhibitor has announced dosing of first patient in Phase 1/1b trail for the treatment of advanced solid tumors.

Brand Name : QTX3046

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 27, 2024

blank

Details:

Enlituo (cetuximab beta) is a EGFR inhibitor indicated in combination with the FOLFIRI regimen as a first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer (mCRC).


Lead Product(s): Cetuximab,Irinotecan Hydrochloride,Calcium Folinate

Therapeutic Area: Oncology Brand Name: Enlituo

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 26, 2024

blank

04

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : Enlituo (cetuximab beta) is a EGFR inhibitor indicated in combination with the FOLFIRI regimen as a first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer (mCRC).

Brand Name : Enlituo

Molecule Type : Large molecule

Upfront Cash : Not Applicable

June 26, 2024

blank

Details:

KRAZATI (adagrasib), a potent oral small-molecule inhibitor of KRASG12C, is indicated in combination with cetuximab for patients with locally advanced or metastatic colorectal cancer.


Lead Product(s): Adagrasib,Cetuximab

Therapeutic Area: Oncology Brand Name: Krazati

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 21, 2024

blank

05

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : KRAZATI (adagrasib), a potent oral small-molecule inhibitor of KRASG12C, is indicated in combination with cetuximab for patients with locally advanced or metastatic colorectal cancer.

Brand Name : Krazati

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 21, 2024

blank

Details:

KRAZATI (adagrasib), a selective oral inhibitor of KRASG12C, is being evaluated with cetuximab for KRASG12C-mutated locally advanced or metastatic colorectal cancer.


Lead Product(s): Adagrasib,Cetuximab

Therapeutic Area: Oncology Brand Name: Krazati

Study Phase: Phase I/ Phase IIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 08, 2024

blank

06

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : KRAZATI (adagrasib), a selective oral inhibitor of KRASG12C, is being evaluated with cetuximab for KRASG12C-mutated locally advanced or metastatic colorectal cancer.

Brand Name : Krazati

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 08, 2024

blank

Details:

PCM-075 (onvansertib) is a PLK-1 inhibitor, which is being evaluated in combination with Folfiri & Bevacizumab for the treatment of second-line RAS-mutated metastatic colorectal cancer.


Lead Product(s): Onvansertib,Cetuximab,Bevacizumab

Therapeutic Area: Oncology Brand Name: PCM-075

Study Phase: Phase IIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 29, 2024

blank

07

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : PCM-075 (onvansertib) is a PLK-1 inhibitor, which is being evaluated in combination with Folfiri & Bevacizumab for the treatment of second-line RAS-mutated metastatic colorectal cancer.

Brand Name : PCM-075

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 29, 2024

blank

Details:

PCM-075 (onvansertib) is a PLK-1 inhibitor, which is being evaluated in combination with Folfiri & Bevacizumab for the treatment of second-line RAS-mutated metastatic colorectal cancer.


Lead Product(s): Onvansertib,Cetuximab,Bevacizumab

Therapeutic Area: Oncology Brand Name: PCM-075

Study Phase: Phase IIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 29, 2024

blank

08

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : PCM-075 (onvansertib) is a PLK-1 inhibitor, which is being evaluated in combination with Folfiri & Bevacizumab for the treatment of second-line RAS-mutated metastatic colorectal cancer.

Brand Name : PCM-075

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 29, 2024

blank

Details:

Krazati (adagrasib) is a selective KRAS G12C inhibitor under evaluation for KRAS G12C-mutated metastatic colorectal cancer.


Lead Product(s): Adagrasib,Cetuximab,BMS-986466

Therapeutic Area: Oncology Brand Name: Krazati

Study Phase: Phase I/ Phase IIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 20, 2024

blank

09

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : Krazati (adagrasib) is a selective KRAS G12C inhibitor under evaluation for KRAS G12C-mutated metastatic colorectal cancer.

Brand Name : Krazati

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 20, 2024

blank

Details:

The company intends to use the proceeds for the supply of NBTXR3, a novel radioenhancer composed of functionalized hafnium oxide crystalline nanoparticles, to advance the Company’s Phase 3 in the US and the EU for the treatment of locally advanced head and neck cancers.


Lead Product(s): Hafnium Oxide,Cetuximab

Therapeutic Area: Oncology Brand Name: NBTXR3

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Jefferies LLC

Deal Size: $34.7 million Upfront Cash: Undisclosed

Deal Type: Public Offering November 07, 2023

blank

10

Nanobiotix

France
arrow
Biotech Showcase
Not Confirmed

Nanobiotix

France
arrow
Biotech Showcase
Not Confirmed

Details : The company intends to use the proceeds for the supply of NBTXR3, a novel radioenhancer composed of functionalized hafnium oxide crystalline nanoparticles, to advance the Company’s Phase 3 in the US and the EU for the treatment of locally advanced head...

Brand Name : NBTXR3

Molecule Type : Small molecule

Upfront Cash : Undisclosed

November 07, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Cetuximab Manufacturers

A Cetuximab manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cetuximab, including repackagers and relabelers. The FDA regulates Cetuximab manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cetuximab API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Cetuximab manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Cetuximab Suppliers

A Cetuximab supplier is an individual or a company that provides Cetuximab active pharmaceutical ingredient (API) or Cetuximab finished formulations upon request. The Cetuximab suppliers may include Cetuximab API manufacturers, exporters, distributors and traders.

click here to find a list of Cetuximab suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Cetuximab JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Cetuximab Drug Master File in Japan (Cetuximab JDMF) empowers Cetuximab API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Cetuximab JDMF during the approval evaluation for pharmaceutical products. At the time of Cetuximab JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Cetuximab suppliers with JDMF on PharmaCompass.

Cetuximab GMP

Cetuximab Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Cetuximab GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cetuximab GMP manufacturer or Cetuximab GMP API supplier for your needs.

Cetuximab CoA

A Cetuximab CoA (Certificate of Analysis) is a formal document that attests to Cetuximab's compliance with Cetuximab specifications and serves as a tool for batch-level quality control.

Cetuximab CoA mostly includes findings from lab analyses of a specific batch. For each Cetuximab CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Cetuximab may be tested according to a variety of international standards, such as European Pharmacopoeia (Cetuximab EP), Cetuximab JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cetuximab USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty